ARCHIVES

Selumetinib Plus Docetaxel Effective in KRAS-Mutant Disease

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

New Protocol Could Improve Survival Of Rare Brain Tumor

October 30, 2009

NCI Places Hold On Genentech Drug Trials, Citing Disagreement Over Intellectual Property Provisions.

March 12, 2010

FDA Approives Lilly’s Alimta For 1st-Line Metastatic NSCLC

September 26, 2008

NCI Plans To Issue Frederick Operations Contract As Sole-Source To SAIC-Frederick Inc. For Up To 10 Years.

November 10, 2006

Does a B from USPSTF Guarantee Coverage? Lung Screening will Define Medicare Stance

March 21, 2014

Lurie Center At Northwestern Wins Core Grant Renewal.

December 7, 2001